Home > Insider Trading > Filing (0001415889-25-000554)

Filing Details

Accession Number:: 0001415889-25-000554
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-01-03 17:10:04
Reporting Period:: 2025-01-02

Accepted Time:: 2025-01-03 17:10:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817713	Janux Therapeutics Inc.	JANX	Pharmaceutical Preparations (2834)	822289112

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1864159	Hollman Andrew Meyer	C/O Janux Therapeutics, Inc. 10955 Vista Sorrento Parkway, Suite 200 San Diego CA 92130	Chief Business Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-01-02	18,000	$0.00	95,473	No	4	A	Direct
Common Stock	Disposition	2025-01-02	2,922	$53.76	92,551	No	4	S	Direct
Common Stock	Disposition	2025-01-02	5,768	$54.51	86,783	No	4	S	Direct
Common Stock	Disposition	2025-01-02	3,444	$55.76	83,339	No	4	S	Direct
Common Stock	Disposition	2025-01-02	1,000	$56.78	82,339	No	4	S	Direct
Common Stock	Disposition	2025-01-02	200	$57.37	82,139	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Acquisiton	2025-01-02	63,000	$0.00	63,000	$53.24

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
63,000		2035-01-01	No	4	A	Direct

Footnotes

Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
The weighted average sale price for the transaction reported was $53.7582 and the range of prices were between $53.20 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $54.5111 and the range of prices were between $54.21 and $55.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $55.7587 and the range of prices were between $55.24 and $56.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $56.7778 and the range of prices were between $56.33 and $57.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $57.365 and the range of prices were between $57.35 and $57.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.